299 related articles for article (PubMed ID: 32330425)
1. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence.
Yeh MT; Bujaki E; Dolan PT; Smith M; Wahid R; Konz J; Weiner AJ; Bandyopadhyay AS; Van Damme P; De Coster I; Revets H; Macadam A; Andino R
Cell Host Microbe; 2020 May; 27(5):736-751.e8. PubMed ID: 32330425
[TBL] [Abstract][Full Text] [Related]
2. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
[TBL] [Abstract][Full Text] [Related]
3. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3.
Yeh MT; Smith M; Carlyle S; Konopka-Anstadt JL; Burns CC; Konz J; Andino R; Macadam A
Nature; 2023 Jul; 619(7968):135-142. PubMed ID: 37316671
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
De Coster I; Leroux-Roels I; Bandyopadhyay AS; Gast C; Withanage K; Steenackers K; De Smedt P; Aerssens A; Leroux-Roels G; Oberste MS; Konopka-Anstadt JL; Weldon WC; Fix A; Konz J; Wahid R; Modlin J; Clemens R; Costa Clemens SA; Bachtiar NS; Van Damme P
Lancet; 2021 Jan; 397(10268):39-50. PubMed ID: 33308429
[TBL] [Abstract][Full Text] [Related]
5. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
6. Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021.
Martin J; Burns CC; Jorba J; Shulman LM; Macadam A; Klapsa D; Majumdar M; Bullows J; Frolov A; Mate R; Bujaki E; Castro CJ; Bullard K; Konz J; Hawes K; Gauld J; Blake IM; Mercer LD; Kurji F; Voorman A; Diop OM; Oberste MS; Modlin J; Macklin G; Eisenhawer M; Bandyopadhyay AS; Zipursky S
MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(24):786-790. PubMed ID: 35709073
[TBL] [Abstract][Full Text] [Related]
7. The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong Positive Selection and Tight Transmission Bottlenecks.
Valesano AL; Taniuchi M; Fitzsimmons WJ; Islam MO; Ahmed T; Zaman K; Haque R; Wong W; Famulare M; Lauring AS
Cell Host Microbe; 2021 Jan; 29(1):32-43.e4. PubMed ID: 33212020
[TBL] [Abstract][Full Text] [Related]
8. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
[TBL] [Abstract][Full Text] [Related]
10. Development of a multiplex RT-PCR assay for the identification of recombination types at different genomic regions of vaccine-derived polioviruses.
Dimitriou TG; Kyriakopoulou Z; Tsakogiannis D; Fikatas A; Gartzonika C; Levidiotou-Stefanou S; Markoulatos P
Virus Genes; 2016 Aug; 52(4):453-62. PubMed ID: 27098645
[TBL] [Abstract][Full Text] [Related]
11. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
[TBL] [Abstract][Full Text] [Related]
12. Poliopolis: pushing boundaries of scientific innovations for disease eradication.
Van Damme P; Coster I; Bandyopadhyay AS; Suykens L; Rudelsheim P; Neels P; Oberste MS; Weldon WC; Clemens R; Revets H
Future Microbiol; 2019 Oct; 14():1321-1330. PubMed ID: 31482728
[TBL] [Abstract][Full Text] [Related]
13. Sabin type 2 polioviruses with intertypic vaccine/vaccine recombinant genomes.
Georgopoulou A; Markoulatos P
Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):792-9. PubMed ID: 11783695
[TBL] [Abstract][Full Text] [Related]
14. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
[TBL] [Abstract][Full Text] [Related]
15. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials.
Wahid R; Mercer LD; De Leon T; DeAntonio R; Sáez-Llorens X; Macadam A; Chumakov K; Strating J; Koel B; Konopka-Anstadt JL; Oberste MS; Burns CC; Andino R; Tritama E; Bandyopadhyay AS; Aguirre G; Rüttimann R; Gast C; Konz JO
Lancet Microbe; 2022 Dec; 3(12):e912-e921. PubMed ID: 36332645
[TBL] [Abstract][Full Text] [Related]
16. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
Minor PD
Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
[TBL] [Abstract][Full Text] [Related]
17. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
18. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine.
Zurbriggen S; Tobler K; Abril C; Diedrich S; Ackermann M; Pallansch MA; Metzler A
Appl Environ Microbiol; 2008 Sep; 74(18):5608-14. PubMed ID: 18641161
[TBL] [Abstract][Full Text] [Related]
19. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization.
Konopka-Anstadt JL; Campagnoli R; Vincent A; Shaw J; Wei L; Wynn NT; Smithee SE; Bujaki E; Te Yeh M; Laassri M; Zagorodnyaya T; Weiner AJ; Chumakov K; Andino R; Macadam A; Kew O; Burns CC
NPJ Vaccines; 2020; 5(1):26. PubMed ID: 32218998
[TBL] [Abstract][Full Text] [Related]
20. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient.
Yang CF; Chen HY; Jorba J; Sun HC; Yang SJ; Lee HC; Huang YC; Lin TY; Chen PJ; Shimizu H; Nishimura Y; Utama A; Pallansch M; Miyamura T; Kew O; Yang JY
J Virol; 2005 Oct; 79(20):12623-34. PubMed ID: 16188964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
